Deal Watch: Kite Inks Novel AML Target Discovery Tie-Up With HiFiBiO
Continuing parent firm Gilead’s busy deal-making year in immuno-oncology, Kite gets option rights to new targets. Boehringer teams with Israel’s BiomX in IBD research.
You may also be interested in...
With Akero’s FGF21 analog showing ability to reduce fibrosis and resolve non-alcoholic steatohepatitis, some analysts think classmate BIO89-100 could yield a better overall profile. NASH data are starting to pour in.
The company paid twice Immunomedics’ last closing stock price to access Trodelvy, approved for triple-negative breast cancer with potential in other solid tumors as monotherapy and in combinations.
In another clear signal that China's innovative drug R&D is coming of age, most global rights to I-Mab's promising early-stage CD47 antibody have been picked up by AbbVie in a deal valued at close to $2bn.